Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension

Advances in Therapy

Volumn 25, Issue 6, 2008, Pages 619-626

  Tuncer, Mustafa ^a   Guntekin, Unal ^a   Gunes, Yilmaz ^a   Gumrukcuoglu, Hasan Ali ^a   Eryonucu, Beyhan ^b  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b FATIH UNIVERSITY   (Turkey)

Author keywords

Atenolol; Diastolic function; Nebivolol

Indexed keywords

ATENOLOL; NEBIVOLOL; ANTIHYPERTENSIVE AGENT; BENZOPYRAN DERIVATIVE; ETHANOLAMINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER FLOWMETRY; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; MALE; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; AGED; COMPARATIVE STUDY; DIASTOLE; DRUG EFFECT; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BENZOPYRANS; DIASTOLE; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 58149340108     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0065-3     Document Type: Article

References (28)

1. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science. 1996;274:740-743.
2. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J. 1998;19:990-1003.
3. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565-1574.
4. Graettinger WF, Bryg RJ. Left-ventricular diastolic dysfunction in hypertension. Curr Opin Cardiol. 1994;9:551-560.
5. Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol. 2002;39:2005-2011.
6. Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med. 1996;156:146-157.
7. Cleland JG. ACE inhibitors for 'diastolic' heart failure? Reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. Eur J Heart Fail. 2001;3:637-639.
8. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II. Causal mechanisms and treatment. Circulation. 2002;105:1503-1508.
9. Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: The Strong Heart Study. Circulation. 2002;105:1928-1933.
10. Mayet J, Shahi M, Poulter NR, Sever PS, Foale RA, Thom SA. Left ventricular diastolic function in hypertension: A 4 year follow-up study. Int J Cardiol. 1995;50:181-188.
11. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: A review. Drugs. 1999;57:633-651.
12. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res. 1998;38:419-431.
13. Ritter JM. Nebivolol: Endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38(suppl 3):s13-s16.
14. Himmelmann A, Kjeldsen SE, Hedner T. Recent hypertension guidelines. JNC-7 and 2003 ESH/ESC. Blood Press. 2003;12:196-197.
15. Pickering TG. Blood pressure measurement issues. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rectors's the Kidney. Philadelphia: WB Saunders; 2000:306-313.
16. Henry WL, de Maria A, Gramiak R. Report of the American Society of Echocardiography Committee on Nomenclature and Standards in two-dimensional echocardiography. Circulation. 1980;62:212-222.
17. Schobel HP, Langenfeld M, Gatzka C, Schmieder RE. Treatment and posttreatment effects of alpha-versus betare-ceptor blockers on left ventricular structure and function in essential hypertension. Am Heart J. 1996;132:1004-1009.
18. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513.
19. Liu GS, Wang LY, Nueten LV, Ooms LA, Borgers M, Janssen PA. The effect of nebivolol on left ventricular hypertrophy in hypertension. Cardiovasc Drugs Ther. 1999;13:549-551.
20. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003;5:621-627.
21. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344-348.
22. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: A randomized, double-blind, crossover study. Circulation. 2001;104:511-514.
23. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: Clinical implications. Drugs. 2002;62:265-284.
24. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res. 1999;43:595-606.
25. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs. atenolol in mild-to moderate essential hypertension: Results of a double-blind randomized multicentre trial. Blood Press. 2003;12(suppl 2):35-40.
26. Cosentino F, Bonetti S, Rehorik R, et al. Nitric-oxide-mediated relaxations in salt-induced hypertension: Effect of chronic beta l-selective receptor blockade. J Hypertens. 2002;20:421-428.
27. Müller-Brunotte R, Kahan T, Malmqvist K, Edner M. Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy. J Hum Hypertens. 2003;17:841-849.
28. Van Bortel LM, de Hoon JN, Kool MJ, Wijnen JA, Vertommen CI, Van Nueten LG. Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol. 1997;51:379-384.